The earnings call highlighted significant achievements in margin expansion, order growth, and strategic partnerships, alongside a record backlog. However, the company faced challenges in the China market and a decline in free cash flow, which affected overall performance. The guidance for 2025 reflects cautious optimism with continued investments in innovation and strategic partnerships.
Company Guidance
During the GE HealthCare fourth quarter and full year 2024 earnings call, the company provided guidance for 2025, projecting revenue growth of 2% to 3%, with a low single-digit decline anticipated in the China market. Excluding China, sales are expected to grow in the mid-single digits, aligning with their global market outlook. The guidance integrates an expected foreign exchange headwind of approximately 1.5% and the impact of new U.S. tariffs on products from China, which are estimated to affect adjusted EBIT by about 10 basis points. Despite these challenges, GE HealthCare is committed to expanding its adjusted EBIT margin by 40 to 50 basis points, targeting a range of 16.7% to 16.8%. The company anticipates adjusted EPS growth of 3% to 6%, setting a full-year target between $4.61 and $4.75, while projecting free cash flow of at least $1.75 billion. For the first quarter of 2025, GE HealthCare expects organic revenue growth of 1% to 2% year-over-year, with adjusted EBIT margin and adjusted EPS remaining approximately flat. The company highlighted ongoing investments in R&D and strategic initiatives as crucial for supporting their long-term growth objectives.
Strong Margin Expansion
Adjusted EBIT margin expanded to 18.7% in Q4, up 260 basis points year-over-year, driven by productivity and volume improvements.
Robust Order Growth
Orders grew by 6% year-over-year, with a book-to-bill ratio of 1.09, the highest since the company's spin-off.
Record Backlog
Exited Q4 with a record backlog of $19.8 billion, up $700 million year-over-year.
New Product Launches
Introduced 40 innovations in 2024, with new products contributing approximately 50% to the year's revenue. Notable upcoming launch: Flyrcado radiopharmaceutical.
Significant Partnerships
Announced a Care Alliance with Sutter Health valued at $1 billion over seven years, contributing to a total of over $5 billion in large deals since the spin-off.
---
GE Healthcare Technologies Inc (GEHC) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GEHC Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Feb 13, 2025
$85.90
$93.48
+8.82%
Oct 30, 2024
$85.24
$87.16
+2.25%
Jul 31, 2024
$82.59
$84.57
+2.40%
Apr 30, 2024
$88.84
$76.16
-14.27%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does GE Healthcare Technologies Inc (GEHC) report earnings?
GE Healthcare Technologies Inc (GEHC) is schdueled to report earning on Apr 29, 2025, TBA Not Confirmed.
What is GE Healthcare Technologies Inc (GEHC) earnings time?
GE Healthcare Technologies Inc (GEHC) earnings time is at Apr 29, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.